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Abstract
With the exception of ApoE4, genome-wide association studies have failed to identify strong
genetic risk factors for late-onset Alzheimer’s disease, despite strong evidence of heritability,
suggesting that many low penetrance genes may be involved. Additionally, the nature of the
identified genetic risk factors and their relation to disease pathology is also largely obscure.
Previous studies have found that a cancer-associated variant of the cell cycle inhibitor gene
p21cip1 is associated with increased risk of Alzheimer’s disease. The aim of this study was to
confirm this association and to elucidate the effects of the variant on protein function and
Alzheimer-type pathology. We examined the association of the p21cip1 variant with Alzheimer’s
disease and Parkinson’s disease with dementia. The genotyping studies were performed
on 719 participants of the Oxford Project to Investigate Memory and Ageing, 225 partici-
pants of a Parkinson’s disease DNA bank, and 477 participants of the Human Random
Control collection available from the European Collection of Cell Cultures. The post mortem
studies were carried out on 190 participants. In the in-vitro study, human embryonic kidney
cells were transfected with either the common or rare p21cip1 variant; and cytometry was
used to assess cell cycle kinetics, p21cip1 protein expression and sub-cellular localisation.
The variant was associated with an increased risk of Alzheimer’s disease, and Parkinson’s
disease with dementia, relative to age matched controls. Furthermore, the variant was asso-
ciated with an earlier age of onset of Alzheimer’s disease, and a more severe phenotype,
with a primary influence on the accumulation of tangle pathology. In the in-vitro study, we
found that the SNPs reduced the cell cycle inhibitory and anti-apoptotic activity of p21cip1.
The results suggest that the cancer-associated variant of p21cip1 may contribute to the loss
of cell cycle control in neurons that may lead to Alzheimer-type neurodegeneration.
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Introduction
Late-onset Alzheimer’s disease (AD) is a neurodegenerative disorder of the elderly that mani-
fests in a myriad of symptoms including memory loss, confusion, and a reduced capacity for
learning [1]. Whilst the heritability of AD is up to 80% [2], so far, only one genetic risk factor,
the E4 variant of the Apolipoprotein E gene (ApoE), is consistently shown to be associated
with an increased risk and reduced age of onset. Genome-wide association studies (GWAS)
have identified additional genetic variants, on genes involved in a variety of pathways, which
may lead to a small increase in AD risk [3–15]; however the individual contribution of each
variant is small. It is likely that the variants work in combination to increase the risk of AD;
and that the exact complement of variants differs from patient to patient.
One possible genetic risk factor for AD is a variant of p21cip1, a cyclin-dependent kinase
inhibitor (CDKI) gene, which is already established to be associated with an increased risk of
some cancers [16–22]. In a preliminary study, the variant (present in ~7% of populations of
European descent according to the Ensembl genome database) was found to be associated with
an increased risk and reduced age of onset of AD [23]. Furthermore, a number of GWAS
[6,24–26] identify the 6p21 loci, on which the p21cip1 gene is located, as associated with AD
risk: compatible with the hypothesis that the p21cip1 variant is a risk factor for AD development
[23].
The G1/S checkpoint is partly regulated by the CDKIs: p21cip1, p27kip1 and p57kip2. P21cip1
inhibits the activity of cyclin/CDK4 and cyclin/CDK2 complexes, which are required for cell
cycle progression through the G1 phase and G1/S checkpoint respectively. It suppresses E2F-
dependent transcription of cell cycle proteins by binding to E2F transcription factor 1 (E2F1)
[27]. It also inhibits the activity of proliferating cell nuclear antigen (PCNA), a protein required
for DNA replication and repair. In addition, p21cip1 has been shown to regulate the G2/M
checkpoint when expressed independently of p53 [28–31]. P21cip1 has an anti-apoptotic role
by inhibiting the stress activated protein kinase (SAPK) and apoptosis signal-regulating kinase
1 (ASK1), as well as inhibiting Fas-mediated apoptosis [32]. A number of additional proteins
interact with p21cip1 to alter its activity. For example, WISp39 has been shown to stabilise the
p21cip1 protein [33]; whilst tumour susceptibility gene 101 (TSG101) enhances the cyclin/CDK
inhibitory activity of p21cip1 by stabilising the p21cip1/cyclin/CDK complexes [33,34].
The association of the rare p21cip1 variant with cancer suggests that the variant has reduced
function or expression: although this has not been experimentally verified. The genetic variant
has substitutions at two DNA bases [19,21]: a cytosine to adenine substitution that induces a
serine to arginine change at codon 31 of p21cip1 (p21 C98A, dbSNP rs1801270); and a cytosine
to thymine change in the 30-untranslated region (UTR) (p21 C70T, dbSNP rs1059234). The
single nucleotide polymorphisms (SNPs) are only associated with cancer when they occur to-
gether [19,21]. The SNP at codon 31 of p21cip1 induces an amino acid change in the zinc finger
domain [20,35] that lies between a cyclin (amino acids: aa 17–24) and CDK binding sites (aa
53–58) [33]. The SNP is located within the binding domains of TSG101 (aa 1–86), WISp39 (aa
28–56), E2F1 (aa 1–90) and the pro-apoptotic proteins: procaspase 3 (aa 1–33), SAPK (aa
1–84) and ASK1 (aa 1–140). It is not within the binding domain of the cyclins (aa 17–24 and
155–157), CDKs (aa 53–58 and 74–79), PCNA (aa 143–160), or various other proteins (re-
viewed in [33]). It is plausible that the SNP may reduce the cell cycle inhibitory activity of
p21cip1 by reducing the strength of binding of p21cip1 to TSG101 and/or E2F1; and may reduce
the anti-apoptotic activity of p21cip1 by reducing the strength of binding to the pro-apoptotic
proteins. The SNP may also reduce the stability of the p21cip1 protein by interfering with
WISp39 binding. Whilst the p21cip1 protein is intrinsically unstructured [36], the serine (polar
uncharged) to arginine (positively charged) change induced by the SNP may alter the
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preference of the p21cip1 protein for certain tertiary structures, potentially altering its interac-
tion with any of its protein targets. The SNP in the 30-UTR of p21cip1 may alter expression, as
this region of the mRNA interacts with various non-coding RNAs and proteins that regulate
mRNA stability and translation efficiency [32].
The reported association of the p21cip1 variant with AD [23] is not surprising when inter-
preted in light of the cell cycle theory of AD, which postulates that neurons degenerate second-
ary to aberrant cell cycle activity [37–39]; and specifically loss of G1/S checkpoint control [23].
To investigate this further, we examine the association of the p21cip1 SNPs with AD and with
Parkinson’s disease (PD) with dementia. We also investigate the association of the p21cip1
SNPs with various phenotypic features of a large AD cohort, including the accumulation of
AD-related pathology in the brain. Furthermore, we investigate the effect of the SNPs on the
function and expression of p21cip1 in vitro, by transiently transfecting human embryonic kid-
ney cells (HEK-293) with either the common or rare p21cip1 variant.
Methods and Materials
Ethics Statement
Full ethical approval and written informed consent were obtained for all studies (NHS Re-
search Ethics Committee approvals: 09/H0107/9, 07/Q2707/98, MREC/00/7/56a).
Subjects
The genotyping studies were performed on 719 participants of the Oxford Project to Investigate
Memory and Ageing (OPTIMA), 225 participants of PD GEN (a Parkinson’s disease DNA bank)
and 477 participants of the Human Random Control (HRC) collections available from the
European Collection of Cell Cultures (ECACC) (HRC plates 1–5). The OPTIMA, PD GEN and
ECACC donors were all of European descent. The clinical diagnoses of the participants of
OPTIMA and PD GEN are summarised in Table 1. Post-mortem brain tissue was available from
190 participants of the OPTIMA cohort through the ThomasWillis Oxford Brain Collection.
The clinical information provided by the OPTIMA team included: age of onset of dementia;
age at death; and the results of annual cognitive performance tests (CAMCOG) [40]. Clinical
diagnosis of AD was made using the NINCDS-ARDRA criteria [41]. The diagnosis of PD was
made using the UK Parkinson’s Disease Society Brain Bank criteria [42]. Dementia in PD pa-
tients (PDGEN cohort) was established based on the presence of progressive deterioration in
intellectual abilities that interferes with activities of daily living [43]. The post mortem brain
tissues were characterised in detail by a clinical neuropathologist. The information available in-
cluded the pathological diagnosis (CERAD protocol) [44] and the severity of AD as defined by
Braak [45]. Subjects where pathologies other than AD were regarded as severe enough to con-
tribute to the clinical dementia syndrome were excluded from the clinico-pathological analyses
[46–48]. Demographic data on these patient groups is in S1 Table and S2 Table.
Table 1. The total number of subjects in each diagnostic category.
Control AD OD AD/PD MCI PD PD D TOTAL
OPTIMA 242 292 84 20 65 4 12 719
PD GEN 0 0 0 0 0 112 113 225
TOTAL 242 292 84 20 65 116 125 944
(AD: Alzheimer’s disease; OD: Other dementia; AD/PD: Alzheimer’s disease with Parkinson’s disease; MCI: Mild cognitive impairment; PD: Parkinson’s
disease; PD D: Parkinson’s disease with dementia; OPTIMA: Oxford Project to Investigate Memory and Ageing; PD GEN: Parkinson’s disease DNA bank).
doi:10.1371/journal.pone.0114050.t001
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Sample Preparation
RNA, DNA and protein were isolated from the lateral temporal, frontal and occipital lobe of
each post-mortem subject by standard TRI-reagent protocol (Sigma). RNA was converted to
cDNA with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems) accord-
ing to the manufacturer’s recommendation. Protein was stored in radio-imunoprecipitation
buffer (0.1M NaCl, 0.01M TrisHCl, 1:500 EDTA, 400μg/ml phenylmethanesulfonylfluoride,
2μg/ml aprotinin and 1% sodium dodecyl sulphate).
p21cip1 Genotyping
The SNPs at codon 31 (RS1801270) and in the 30-UTR of p21cip1 (RS1059234) were genotyped
as described in [19], using restriction enzymes Bsma1 and PstI (Biolabs) as recommended by
the manufacturer.
ELISA
Five markers of AD-related pathology were quantified by ELISA in the temporal, frontal and
occipital lobe of each subject (Table 2) [49–52]. A protein sample with a high quantity of the
protein-of-interest was selected for each standard curve; and samples analysed in triplicate. For
each ELISA, 100 μl of protein, diluted in 0.1M Carbonate buffer (pH 9.6) to the optimal loading
concentration (see Table 3), was loaded per well and incubated overnight at 4°C. Following
blocking with 1% bovine serum albumin (Sigma) in PBS (Sigma), the samples were incubated
with primary antibody at 4°C overnight, with secondary antibody at room temperature (RT)
for 2 hours and with Streptavidin-HRP (1:200, R&D Systems) at RT for 2 hours. For antibody
concentrations see Table 3. The reactions were visualised with o-phenylenediamine dihy-
drochloride (SIGMAFAST OPD); and reaction stopped with 25μl of 4M H2SO4. The calibra-
tion curve, obtained from the serial dilution of the standard curve sample, was used to estimate
concentration of the protein based on their optical density readings.
Q-PCR
Q-PCR was used to quantify p21cip1 mRNA in the frontal lobe of each subject, with normalisa-
tion to beta-actin content. Q-PCR systems were designed with the Universal Probe Library De-
sign Centre (Roche Diagnostic); and consisted of primers: 50-TGGGTGGTACCCTCTGGA-30
and 50-TGAATTTCATAACCGCCTGTG-30 with Universal probe 12 for p21cip1; and primers:
50-TCAGCTGTGGGGTCCTGT-30 and 50-GAAGGGGACAGGCAGTGAG-30 with Universal
probe 24 for beta-actin. Each 20μl Q-PCR reaction consisted of 2μl neat cDNA, 2.5μM of each
Table 2. Markers of AD-related pathology that were quantiﬁed by ELISA in the brain.
Marker Description
Beta-amyloid 39–43 amino acid cleavage product of APP that accumulates in the
brain in AD.
Phospho-tau (p-tau) Hyperphoshorylated (Ser 202/Thr 205) version of tau found in
neuroﬁbrillary tangles.
Neuroﬁbrillary tangle (NFT)
(epitope DC11)
A protein aggregate that accumulates in neurons in AD. DC11 is a
conformational epitope of the neuroﬁbrillary tangle that is highly AD
speciﬁc.
Synaptophysin 38kDa glycoprotein located on neuronal synapses. A marker of
synaptic density.
Growth associated protein 43
(GAP-43)
Neuron speciﬁc protein expressed on axonal growth cones during
synaptic remodelling. A marker of synaptic remodelling activity.
doi:10.1371/journal.pone.0114050.t002
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primer, 0.25μMUniversal probe (Roche) and 2x Absolute Q-PCRmix (Thermo Scientific).
Products were amplified with an initial 15 minute step at 95°C, followed by 50 cycles of 96°C for
15 sec, 62°C (beta-actin) or 58°C (p21cip1) for 30 sec, and 72°C for 30 sec.
Cell Culture and Transfection
The prolonged consistent overexpression of p21cip1 leads to a complete cessation of cell divi-
sion [53] and would prevent the detection of subtle effects on cell cycle regulation or apoptosis.
Therefore we have chosen transient transfection in human embryonic kidney cells (HEK-293,
Invitrogen) to study the effects of the p21cip1 variants on cell cycle, apoptosis and cell differenti-
ation. The HEK-293 cells are easy to grow and easy to transfect. The cell line is capable of
generating functional, mature proteins and is widely used for the biochemical/cell biological
evaluation of expressed proteins in concert with functional analyses to establish pharmacologi-
cal effects [54].
The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 4500 mg glucose/litre (Sigma), 10% foetal calf serum (FCS) gold (PAA), and 2mM L-
glutamine (Gibco), until 90–95% confluence. Cells were transfected with plasmids (ready to
transfect TrueClones from Origene, in pCMV6-XL5 and pCMV6-XL4) designed to express
either the common p21cip1 variant (IMAGE ID 2821049), the rare p21cip1 variant (with SNP at
codon 31 and in the 30-UTR; IMAGE ID 2822909), or no p21cip1 (empty vector negative con-
trol, EV NC, pCMV6-XL5) with Lipofectamine-2000 (Invitrogen). The presence/absence of
the two polymorphisms in the purchased clones was confirmed by sequencing (Invitrogen
service). Before transfection the cells were grown in full medium to reach 90–95% confluence
(approximately 2 days). In preparation for transfection, 30μg of plasmid DNA was diluted
in 1.875ml of Opti-MEM reduced serum medium (Gibco); and 75μl of Lipofectamine 2000
(Invitrogen) diluted in 1.875ml Opti-MEM. After 5 minute incubation, the two mixtures were
combined and incubated at RT for 20 minutes. The 3.75ml mixture was added to a flask of
cultured cells and mixed by gentle rocking. After 36 hours incubation the cells were dislodged
with 1mM EDTA and collected for RNA and protein extraction or seeded into 96 well plates
for cytometry. Transfection efficiency was calculated using the assumption that p21cip1 trans-
fected cells stop proliferating while the non-transfected cells proliferate at their original prolif-
eration rate of ~1 population doubling in 36 hours [55].
Following an overnight incubation the cells in the 96 well plates were fixed with Glyofixx for
p21cip1 and beta-actin immunolabelling. The fixed cells were sequentially incubated with
blocking solution (5% BSA and 0.1% triton-X in PBS), primary and secondary antibody, and
propidium iodide (PI, 10μg/ml) supplemented with RNaseA (100μg/ml), prior to immunofluo-
rescence, and combined image analysis and cytometry, with the Acumen Explorer Cytometer
Table 3. The protein loading concentration and antibody information corresponding to each ELISA.
Protein Loading conc.
(μg/ml)
Primary antibody Secondary antibody
Beta-amyloid 2 Mouse monoclonal to amyloid-β (1:5000, Dako) Biotinylated polyclonal rabbit anti-mouse IgG (1:2000, Dako)
p-tau 2.5 Mouse monoclonal to AT8 (1:1000, Innogenetics) Biotinylated polyclonal rabbit anti-mouse IgG (1:2000, Dako)
DC11 4 Mouse monoclonal to DCII (1:500, Sigma) Biotinylated polyclonal rabbit anti-mouse IgG (1:2000, Dako)
GAP-43 2 Rabbit polyclonal to GAP43 (1:1000, Chemicon) Biotinylated polyclonal swine anti-rabbit IgG (1:2000, Dako)
Synapto-physin 2 Mouse monoclonal to synaptophysin (1:1000, Dako) Biotinylated polyclonal rabbit anti-mouse IgG (1:2000, Dako)
p21cip1 4 Rabbit polyclonal to p21cip1 (1:500, ABcam) Biotinylated polyclonal swine anti-rabbit IgG (1:2000, Dako)
doi:10.1371/journal.pone.0114050.t003
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(TTP Labtech, Acumen Explorer Software version 3.1.12.). The antibodies were rabbit poly-
clonal to p21cip1 (ABcam, 1:500), mouse monoclonal to beta-actin (ABcam, 1:500), anti-rabbit
IgG FITC (ABcam, 1:200) and anti-mouse IgG FITC (ABcam, 1:200).
The PI stained cultures provided measurements of DNA content and nucleus size, and were
analysed by standard cytometry methods [56] to determine cell cycle phase of the individual
cells in the sample. The immunolabelled cells provided measurements of p21cip1 and beta-actin
protein content per cell, and per nucleus, and allowed the categorisation of cells based on ex-
pression (positive/ negative) and subcellular localisation (Fig. 1). Single cells were defined by
the size of the cell and shape of the PI distribution in the nucleus (as seen in fig. 1 panes C and
F). The DNA histograms were gated based on published methods [57]. The gates were set
separately for each 96 well plate to eliminate the effect of slight changes in excitation. The
percentage of cells in G1, S and G2/M phases of the cell cycle were calculated as a fraction of
the euploid cell population. Cells with sub-G1 DNA content were categorised as apoptotic
while single cells with above-G2 DNA content were regarded as polyploid. The percentage of
apoptotic cells was calculated as a fraction of the single cells. Clumps of multiple cells (identi-
fied by multiple nuclei within the same ‘object’) and debris (no DNA trace specific for nuclei
as shown in Fig. 1C) were excluded from the analysis. Cytometric analysis of the cell cycle
phases and apoptosis was carried out separately for p21cip1 positive and negative cells (as
defined above) within each population. Analysis was carried out from 8 technical replicates
of more than 5000 cells each at the time. The transfections were repeated on three separate
occasions. The extracted RNA was converted to cDNA as described and used for p21cip1
Q-PCR analysis.
Figure 1. HEK293 cells transfected with p21cip1. Image of cells acquired from the Acumen cytometer. The p21cip1 was labelled by
immunohistochemistry (green fluorescence). The DNA is labelled red by the PI. Panel A: The cell with the blue edge is an example of what we would accept
as cytoplasmic protein expression. Panel B is the green fluorescence intensity histogram (as measured by the cytometer) over the surface of the same cell
(with the blue edge in panel A) indicating a relatively uniform protein distribution in the cytoplasm around the nucleus. Panel C is the distribution histogram of
the red fluorescence (DNA) from the same cell (with the blue edge in panel A). The distribution of the DNA is characteristic for a single cell. Panel D: The cell
with the blue edge is an example of what we would accept as nuclear protein expression. Panel E is the green fluorescence intensity histogram (protein
content as measured by the cytometer) over the surface of the same cell (with the blue edge in panel D). Panel F is the red fluorescence (DNA) from the
same cell (with the blue edge in panel D). The overlap and identical distribution patterns of the protein (green label) and DNA (red label) is characteristic for
nuclear proteins.
doi:10.1371/journal.pone.0114050.g001
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Statistical Analysis
Data was analysed with the MedCalc statistical package, version 13.0.2.0. Departure from the
Hardy-Weinberg equilibrium was tested using the Chi-square test. Odds ratios (OD) with 95%
confidence intervals (CI) were used to determine the association of the p21cip1 variant with AD
and with PD with dementia, relative to age-matched controls. In the post-mortem study, the
D’Agostino-Pearson normality test was used to assess the distribution of datasets prior to sta-
tistical analysis and the most appropriate test selected in each case (for data that followed a nor-
mal distribution: ANOVA or MANOVA; for data that did not follow a normal distribution:
Kruskal-Wallis). To eliminate the need for subgroups defined by the severity of AD, Z-scores
were calculated for the pathology data taking into account the disease severity as defined by
Braak [45]. The Z-scores were analysed by ANOVA.
Previous experiments with the same cell line indicate that even a 3 fold increase in the ex-
pression of the cyclin dependent kinase-like 3 (cdkl3, which drives the transition from G1 to
S phase to increase cell proliferation) leads to only modest changes in proliferation rate (19%
change) and cell cycle (11% change in the G1 population) [55]. Therefore any differences be-
tween the effect of the two p21cip1 variants, even if significant, may be modest and could be eas-
ily masked by the fast growing non-transfected cells. Additionally transient transfection is a
stressful procedure, with relatively large experimental variability and cell cycle kinetics is great-
ly influenced by cell density in cultures. Therefore changes induced by the p21cip1 variants
(common and rare) were analysed by comparing the cell populations successfully transfected
with p21cip1 to both the empty vector negative control cells (EV NC) and to the non-trans-
fected cell population within the same well. Differences between means larger than 2 standard
deviations were accepted as statistically significant.
Results
The rare p21cip1 haplotype had alterations at two polymorphic sites: at codon 31 (a cytosine to
adenine substitution) and in the 30-UTR (a cytosine to thymine substitution). Subjects that had
one or two copies of the rare haplotype (with both substitutions) were classed as having variant
p21cip1, whereas subjects that did not have a copy of the rare haplotype were classed as having
common p21cip1.
Of the 477 ECACC Human Random Control subjects that were genotyped, 435 were
homozygous for the common variant of p21cip1, 39 were heterozygous, and 3 were homozygous
for the rare variant. Of the 944 live and post-mortem subjects in the OPTIMA and PD GEN
cohorts, 852 were homozygous for the common variant, 89 were heterozygous, and 3 were
homozygous for the rare variant. The allele frequency of the rare variant in the ECACC
Human Random Control cohort, and in the combined OPTIMA and PDGEN cohort, was
0.047 and 0.053 respectively (Table 4). The distribution of the rare p21cip1 haplotype followed
the Hardy-Weinberg equilibrium in all the investigated cohorts. The presence of the variant
was significantly associated with an increased risk of AD (odds ratio 1.796, p = 0.030, 95% CI:
1.057 to 3.051) and with PD with dementia (odds ratio 2.052, p = 0.022, 95% CI: 1.108–3.798),
relative to age-matched controls (Table 5). There was a trend for an association between the
rare variant and PD with dementia, relative to PD without dementia (age matched subjects),
but the result failed to reach statistical significance (Table 5). Prior to the age of 75, the variant
was associated with a reduced disease (dementia) free survival in relation to AD (hazard
ratio 1.698, p = 0.017) (Fig. 2) and PD with dementia (hazard ratio 3.239, p< 0.001) (Fig. 3).
Neither association was present above the age of 75 (data not shown). The sample size
was not big enough to analyse a possible synergy between the p21cip1 haplotype and the
ApoE genotype.
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Post-Mortem Pathology Study
In the post-mortem study, the severity of AD was defined according to the Braak staging sys-
tem[45]: with entorhinal, limbic and neocortical stage subjects in a preclinical, mild and ad-
vanced stage of AD respectively. The distribution of the ApoE genotypes in subgroups defined
by the AD severity was similar to that of published datasets [58]. There was no significant dif-
ference in the distribution of the ApoE genotypes, or in the frequency of the ApoE4 allele, in
the common p21cip1 group compared to the variant p21cip1 group, irrespective of the severity
of AD (data not shown).
There was a trend for the p21cip1 variant to be more common in subjects with advanced AD
(allele frequency: 0.081) compared to subjects with pre-clinical (allele frequency: 0.052) and
mild AD (allele frequency: 0.053) (Table 6). However, as we had a relatively small sample size,
the result (odds ratio: 1.587) failed to reach statistical significance. The p21cip1 genotype had no
effect on the age at death, the duration of AD, or the cognitive performance of subjects just
prior to death, irrespective of AD severity (data not shown). However, of the subjects with ad-
vanced AD at post-mortem, the subjects with variant p21cip1 had an earlier age of onset of AD
than subjects with common p21cip1 (p = 0.016) (Fig. 4). This effect on the age of onset was not
present in the subjects in the earlier stages of AD.
Of the investigated pathological features, the p21cip1 genotype had the greatest effect on the
accumulation of tau pathology in the brain. At post-mortem, subjects with variant p21cip1 had
significantly greater amounts of hyperphosphorylated tau (p-tau) and neurofibrillary tangles
(NFT) in the frontal lobe than subjects with common p21cip1, irrespective of the disease severi-
ty (p = 0.003 and p = 0.003 for p-tau and NFT respectively). Subjects with variant p21cip1 also
had significantly greater p-tau and NFT accumulation in the occipital lobe than subjects with
Table 4. The allele frequency of the p21cip1 variant in the various study groups.
Subgroup Collection Variant P21cip1 allele count Common P21cip1 allele count Variant allele frequency
All subjects ECACC HRC 45 909 0.047
All subjects OPTIMA and PD GEN 95 1793 0.053
Controls and non-AD dementia OPTIMA 23 637 0.035
AD OPTIMA 38 586 0.061
PD without dementia OPTIMA and PD GEN 11 213 0.049
PD with dementia OPTIMA and PD GEN 20 270 0.069
For the OPTIMA and PD GEN collection, the variant allele frequency was analysed for the cohort as a whole, and in separate groups deﬁned by diagnosis
(diagnostic criteria outlined in the methods). AD refers to Alzheimer’s disease; PD to Parkinson’s disease; OPTIMA to the Oxford Project to Investigate
Memory and Ageing; PD GEN to the Parkinson’s disease DNA Bank; and ECACC HRC to the European Collection of Cell Cultures Human Random
Control.
doi:10.1371/journal.pone.0114050.t004
Table 5. Odds ratios for disease in relation to the rare p21cip1 variant.
DIAGNOSIS Odds ratio (variant relative to common) P-value 95% CI
AD (versus controls and non-AD dementia) 1.796 < 0.05 1.057–3.051
PD with dementia (versus controls and non-AD dementia) 2.052 < 0.05 1.108–3.798
PD with dementia (versus PD without dementia) 1.433 Not signiﬁcant
The OPTIMA and PD Gen cohorts were separated into groups deﬁned by diagnosis based on the diagnostic criteria outlined in the methods. Odds ratios
in relation to the p21cip1 variant were calculated for the disease groups compared to age-matched controls.
doi:10.1371/journal.pone.0114050.t005
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common p21cip1: with p-tau results reaching statistical significance in subjects with mild and
advanced AD only (p = 0.014 and p = 0.029 respectively) and NFT results reaching significance
irrespective of the severity of disease (p = 0.023) (Fig. 5). The p21cip1 genotype had no effect on
the accumulation of tau pathology in the temporal lobe, irrespective of AD severity (data not
shown).
Figure 2. Kaplan-Meier probability distribution of disease free survival prior to the age of 75. The
disease in question was dementia associated with AD. The graph shows the disease free survival probability
of subjects prior to the age of 75, in subgroups defined by the p21cip1 genotype. Prior to the age of 75, the
variant p21cip1 was associated with a significant reduction in the disease free survival compared to the
common p21cip1 (hazard ratio: 1.698, p-value: 0.017). The x-axis represents the age in years. The y-axis
represents the survival probability expressed as a percentage. The solid black line represents subjects that
were homozygous for the common p21cip1. The broken grey line represents subjects that were heterozygous
or homozygous for the variant p21cip1.
doi:10.1371/journal.pone.0114050.g002
Figure 3. Kaplan-Meier probability distribution of disease free survival prior to the age of 75. The
disease in question was dementia in Parkinson’s disease. The graph shows the disease free survival
probability of subjects prior to the age of 75, in subgroups defined by the p21cip1 genotype. Prior to the age of
75, the variant p21cip1 was significantly associated with a reduction in the disease free survival compared to
the common p21cip1 (hazard ratio: 3.239, p-value< 0.001). The x-axis represents the age in years. The y-axis
represents the survival probability expressed as a percentage. The solid black line represents subjects that
were homozygous for the common p21cip1. The broken grey line represents subjects that were heterozygous
or homozygous for the variant p21cip1.
doi:10.1371/journal.pone.0114050.g003
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We analysed the effect of the p21cip1 genotype on the spread of tau pathology from the tempo-
ral to the frontal and occipital lobe. Spread of pathology was defined as the ratio of the amount of
pathology in the region less severely affected by AD over that in the more severely affected region.
We found that subjects with variant p21cip1 had significantly greater p-tau spread from the tem-
poral to the frontal lobe than subjects with common p21cip1, irrespective of the severity of disease
(p = 0.025) (Fig. 6A). There was a trend (not statistically significant) for subjects with variant
p21cip1 to have greater p-tau spread from the temporal to the occipital lobe than subjects with
common p21cip1 (Fig. 6B). The spread of NFT from the temporal to the frontal and occipital lobe
was independent of the p21cip1 genotype, irrespective of disease severity (data not shown).
The accumulation of beta-amyloid was independent of the p21cip1 genotype in all the brain
regions investigated (temporal, frontal and occipital) (data not shown). Although in the frontal
lobe there was a trend for the p21cip1 variant to be associated with lower synaptic densities and
a reduction in the synaptic remodelling activity compared to the common p21cip1, the result
did not reach statistical significance (data not shown). The synaptic density and the remodel-
ling activity were independent of the p21cip1 genotype in the temporal and occipital lobe (data
not shown).
The amount of p21cip1 protein found in the temporal lobe, but not in the frontal and occipi-
tal lobe, was raised in subjects with more severe AD (p = 0.007) (Fig. 7). However, p21cip1 pro-
tein expression was independent of the p21cip1 genotype in all the brain regions examined
Table 6. The allele frequency of the p21cip1 variant in groups deﬁned by the severity of AD.
Diagnosis Variant allele count Common allele count Variant allele frequency
Pre-clinical 4 72 0.052
Mild AD 7 125 0.053
Advanced AD 14 158 0.081
The diagnosis was deﬁned according to the Braak staging system: with entorhinal, limbic and neocortical
stage subjects in a pre-clinical, mild and advanced stage of AD respectively.
doi:10.1371/journal.pone.0114050.t006
Figure 4. The effect of the p21cip1 genotype on the age of onset of AD.Of the subjects with advanced AD
at post-mortem, the subjects with the variant p21cip1 had a significantly lower age of onset than subjects with
the common p21cip1 (p-value: 0.016). The x-axis represents the p21cip1 genotype, with com and var
representing subjects with the common and variant p21cip1 respectively. The y-axis represents the age at
onset of AD in years. The top of the bars represent the mean. The error bars represent the standard error of
the mean (SEM). Statistical test: one-way ANOVA.
doi:10.1371/journal.pone.0114050.g004
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(data not shown). The p21cip1 mRNA expression and the protein per mRNA ratio were inde-
pendent of both the severity of AD and the p21cip1 genotype (analysed only in the frontal lobe).
Multiple regression analysis showed that the expression of p21cip1 protein was dependent on
the NFT content (R2 = 0.1, p = 0.003) and independent of both p21cip1 mRNA expression and
disease severity (analysed in the frontal lobe only). Data in S3 Table.
In-Vitro Study
In order to elucidate the effect of the p21cip1 SNPs on the function of the protein in-vitro,
human embryonic kidney cells (HEK-293, Invitrogen), intrinsically homozygous for the com-
mon variant of p21cip1, were transiently transfected with a vector designed to express either the
common p21cip1, variant p21cip1 (with both SNPs), or no p21cip1 (EV NC). P21cip1 content at
the mRNA and protein level were determined by Q-PCR and Acumen Cytometry respectively.
Confirming the success of transfection, the p21cip1 transfected cells had significantly greater
p21cip1 mRNA and protein expression than the control (EV NC); and there was no significant
Figure 5. The effect of the p21cip1 genotype on the expression of tau pathology in the brain. Panel A and B: The graphs shows the mean p-tau levels in
the brain of subjects in subgroups defined by the severity of AD and the p21cip1 genotype (Panel A: frontal lobe, Panel B: occipital lobe). The x-axis
represents the severity of AD as defined by Braak: E = entorhinal stage, L = limbic stage, N = neocortical stage. The y-axis represents the amount of p-tau
detected in the relevant lobe by ELISA with a marker for AT8 (arbitrary units). Light grey bars: subjects with common p21cip1; dark grey bars: subjects with
variant p21cip1. Statistical test: Kruskal Wallis. Panel C, D, E and F: Z-scores were calculated for the amount of p-tau and NFT detected in the temporal,
frontal and occipital lobe of each subject, taking into account the severity of AD as defined by Braak. This eliminated the need for subgroups defined by the
disease severity. The graphs show the mean z-scores in subgroups defined by the p21cip1 genotype. Panel C: p-tau in the frontal lobe. Panel D: p-tau in the
occipital lobe. Panel E: NFT in the frontal lobe. Panel F: NFT in the occipital lobe. The x-axes represent the p21cip1 genotype, with com and var representing
subjects with common and variant p21cip1 respectively. The y-axes represents the p-tau or NFT content of the relevant brain region as determined by ELISA
with markers for AT8 and DC11 respectively (arbitrary units). Statistical test: one-way ANOVA. The top/bottom of the bars represent the mean. The error bars
represent the SEM.
doi:10.1371/journal.pone.0114050.g005
Figure 6. The effect of the p21cip1 genotype on the spread of p-tau pathology in the brain. Panel A and B. The spread of p-tau pathology was defined as
the ratio of the amount of p-tau in the region less severely affected by AD (Panel A: frontal lobe; Panel B: occipital lobe) over that in the more severely
affected region (temporal lobe). Z-scores were calculated for the spread of p-tau taking into account the disease severity as defined by Braak, which
eliminated the need for subgroups defined by the disease severity. The graphs show the mean z-scores of p-tau spread in subgroups defined by the p21cip1
genotype. The x-axis represents the p21cip1 genotype, with com and var representing subjects with the common and variant p21cip1 respectively. The y-axis
represents the spread of p-tau calculated from data determined by ELISA with a marker for AT8 (arbitrary units). The error bars represent the SEM. Statistical
test: one-way ANOVA of z-scores.
doi:10.1371/journal.pone.0114050.g006
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difference (in terms of expression) between the transfectants containing the common or vari-
ant form of p21cip1 (Table 7). Cells transfected with variant p21cip1 expressed 21.9% more
p21cip1 protein per mRNA than cells transfected with common p21cip1.
Within each well the gates for the DNA histogram were set using the whole population
(Fig. 8) but cells that were positive and negative for p21cip1 protein (as determined by Acumen
Cytometry Fig. 1) were analysed separately to avoid misinterpretation of data as a result of un-
equal transfection efficiency or seeding density. The transfection efficiency was relatively low
for both variants (12–13% p21cip1 positive cells after 36 hours; ~21% transfection efficiency)
but the number of p21 positive cells was above 1000/well to allow meaningful analysis. The
p21cip1 genotype had no effect on the p21cip1 protein expression per cell, p21cip1 protein density
per nucleus, or on the percentage of p21cip1 nuclear positive cells when only p21cip1 positive
cells were analysed (Fig. 9). This indicates that the SNPs did not alter either the expression or
the nuclear translocation efficiency of the p21cip1 protein.
Figure 7. The association of the disease stage with p21cip1 expression in the temporal lobe. Subjects
with more severe AD had a significantly greater amount of p21cip1 protein in the temporal lobe than subjects
in an earlier stage of the disease (p-value: 0.007). The x-axis represents the severity of AD as defined by
Braak: E = entorhinal stage, L = limbic stage, N = neocortical stage. The y-axis represents the p21cip1 protein
content of the temporal lobe as determined by ELISA (arbitrary units). The top of the bars represent the mean
and the error bars the SEM. Statistical test: Kruskal Wallis.
doi:10.1371/journal.pone.0114050.g007
Table 7. The ratio of p21cip1 protein to mRNA in the cells transfected with the different variants of p21cip1.
P21cip1 mRNA content (relative to
control, expressed as multiple)
P21cip1 protein content (relative to
control, expressed as multiple)
p21cip1 protein/ mRNA content (relative to
common p21cip1, expressed as percentage
change)
Common
p21cip1
x 298 x 7.2 N/A
Variant
p21cip1
x 275 x 8.1 21.9%
The p21cip1 protein and mRNA results were normalised to the equivalent value for beta-actin.
doi:10.1371/journal.pone.0114050.t007
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Despite comparable expression and nuclear translocation efficiency, the effect of p21cip1 on
the cell cycle kinetics and apoptotic activity was dependent on the p21cip1 genotype. The in-
crease in the G2 population (G2 phase arrest) was significantly stronger with the common
p21cip1 (41% relative to non-transfected cells and 31% relative to the EV NC) compared to
variant p21cip1 (20% relative to non-transfected cells and 12% relative to the EV NC). Further-
more, the reduction in the rate of apoptosis was significantly greater with the common p21cip1
(42% relative to non-transfected cells and 30% relative to the EV NC) compared to variant
p21cip1 (49% relative to non-transfected cells and 43% relative to the EV NC) (Fig. 10, Data in
S4 Table).
Whilst both forms of p21cip1 increased the beta-actin expression per cell, the size of the in-
crease was dependent on the genotype. Cells transfected with common p21cip1 expressed a sig-
nificantly greater amount of beta-actin per cell (~18% more than the EV NC) than cells
transfected with variant p21cip1 (~11% more than the EV NC) (Fig. 11). The p21cip1 expressing
cells were also significantly larger than their non-transfected counterparts. However, the pres-
ence of the SNPs did not alter this p21cip1-dependent increase in cell size (data not shown).
Discussion
The CDK inhibitor: p21cip1 is capable of inducing cell cycle arrest at the G1/S and G2/M check-
points [59]. It is up-regulated on a transcriptional level in response to p53 (a DNA-damage in-
duced transcription factor), and inhibits CDK2/cyclin A and CDK2/ cyclin E, thereby acting as
a G1/S checkpoint inhibitor. Additionally, a number of studies indicate that p21cip1, expressed
independently of p53, induces cell cycle arrest at the G2/M checkpoint [28–31]. P21cip1 has a
number of additional cellular functions, such as DNA replication and repair [60] and the pre-
vention of apoptosis [61]. The subcellular localisation of p21cip1 may dictate its function: with a
nuclear location required for its cell cycle regulatory role, and a cytoplasmic location required
for its anti-apoptotic role [62,63]. The p21cip1 protein has specific binding sites for a large num-
ber of different proteins, including cyclins, CDKs, PCNA, ASK1, procaspase 3, SAPK, TSG101,
E2F-1, and WISp39 [33].
We hypothesised that two cancer associated SNPs of p21cip1 may reduce p21cip1 protein ex-
pression or function, thereby contributing to the loss of G1/S checkpoint control in neurons
that is postulated to be a cause of neurodegeneration in AD. Our results confirmed that p53-
independent expression of p21cip1 leads to G2/M checkpoint inhibition and protection against
Figure 8. DNA distribution histograms from HEK293 cells transfected with p21cip1. Representative DNA distribution histograms of single cells from the
Acumen cytometer (black bars). The debris and multiple cells (white bars) were excluded from the analysis. Panel A: Typical DNA content histogram of
single cells following the transfection with the empty vector (EV NC). Panel B: Typical DNA content histogram of single cells following transfection with the
common variant of p21cip1. Panel C: Typical DNA content histogram of single cells following transfection with the rare variant of p21cip1.
doi:10.1371/journal.pone.0114050.g008
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Figure 9. The effect of the p21cip1 genotype on the expression of p21cip1. The graphs plot the amount of
p21cip1 protein expressed per cell (Panel A); the p21cip1 protein density per nucleus (Panel B) and the
percentage of nuclear positive cells (Panel C) of cells transfected with either the common or variant p21cip1.
Only cells that were positive for p21cip1 protein, as determined by Acumen Cytometry, were included in the
analysis. To allow comparison of the cells transfected with the different variants of p21cip1, the expression of
p21cip1 in each transfected population was normalised to that in the common p21cip1 transfected population.
All results concerning p21cip1 expression in the common population are therefore displayed as 100%. On the
x-axis: com p21 represents cells transfected with common p21cip1; var p21 represents cells transfected with
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apoptosis. We found that the SNPs, although they did not affect expression or nuclear translo-
cation, reduced both the cell cycle inhibitory and anti-apoptotic activity of p21cip1.
Additionally, the SNPs did not alter the p21cip1-dependent increase in cell size, but reduced
the p21cip1- dependent increase in cellular beta-actin expression. Beta-actin is an integral com-
ponent of the cellular cytoskeleton, which is extensively re-organised during the cell cycle and
is upregulated during cellular differentiation [64,65]. The effect of the SNPs on the up-regula-
tion of beta-actin suggests that the SNPs reduced the ability of p21cip1 to induce differentiation.
Furthermore, the p21cip1 SNPs altered the p21cip1 protein to mRNA ratio: with a significantly
greater amount of p21cip1 protein found per mRNA for variant p21cip1 than for the common
p21cip1. This suggests that the SNPs either reduced the stability of the p21cip1 mRNA or re-
duced the rate of degradation of the p21cip1 protein.
Whilst we cannot draw conclusions on the individual effects of the p21cip1 SNPs, it is
known that the SNP at codon 31 of p21cip1 induces an amino acid change within the binding
domain of WISp39, ASK1, procaspase 3, SAPK, TSG101 and E2F-1 [33]. WISp39 increases the
stability of the p21cip1 protein; ASK1, procaspase 3 and SAPK are pro-apoptotic proteins that
are inhibited by p21cip1; TSG101 increases the stability of p21cip1/cyclin/CDK2 complexes,
thereby enhancing the cell cycle inhibitory effects of p21cip1; whereas E2F-1 promotes E2F-
dependent transcription of cell cycle promoting proteins and is inhibited by p21cip1 binding.
The SNP is likely responsible for a loss of strength of binding of p21cip1 to some or all of these
proteins. The reduction in the cell cycle inhibitory activity induced by the SNPs may be due to
a loss of strength of binding of p21cip1 to TSG101 and E2F-1, whereas the reduction in the anti-
apoptotic activity may be due to a loss of strength of binding to the pro-apoptotic proteins
(ASK1, procaspase 3 and SAPK). In addition, the SNP may alter the affinity of the p21cip1 pro-
tein for its binding partners, by altering its preferred tertiary structure. Whilst the p21cip1 pro-
tein is an intrinsically unstructured protein [36], its preference for certain conformational
arrangements will depend on the charges of its residues. The serine (polar uncharged amino
acid) to arginine (positively charged amino acid) change induced by the SNP at codon 31 may
lead to a change in the preference of the p21cip1 protein for its binding partners.
Although the SNP at codon 31 lies within the binding domain of WISp39 (a protein that
stabilises p21cip1), we found that the SNP was associated with a greater protein per mRNA
ratio. Further studies are necessary to elucidate whether this effect is due to altered protein or
mRNA stability [32].
The requirement for co-localisation of the p21cip1 SNPs for an association with cancer
[19,21] suggests that the individual effects of the SNPs are required together for a significant
loss of G1/S checkpoint control. We have shown that the SNPs, when together, reduce the
function of the p21cip1 protein and may alter the stability of it. All our findings were consistent
with the known association of the p21cip1 SNPs with cancer in populations of European descent
[16–22]: the population group where the SNPs are the least prevalent [66]. The relatively small
effect of the variant on the p21cip1 function, together with the possible compensatory effect of
other members of the kip/cip family, may explain the low-penetration of this risk factor for
cancer [20]. The lack of association between these SNPs and cancer in other ethnic groups [20]
may be due to other genetic and environmental factors that may either impact on the function-
al effects of the SNPs or affect the development of cancer.
variant p21cip1. The y-axis represents the p21cip1 protein expression per cell (Panel A), the p21cip1 density per
nucleus (Panel B), and the percentage of nuclear positive cells (Panel C) expressed as a percentage of that
in the population transfected with common p21cip1. The top of the bars represent the mean. The error bars
represent the SEM. Analysis was carried out from 8 technical replicates of more than 5000 cells each.
doi:10.1371/journal.pone.0114050.g009
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Figure 10. The effect of the p21cip1 genotype on the cell cycle and apoptotic activity. Panel A: The fraction of cells in the G1 phase of the cell cycle
(from the euploid population) in the different cell populations. EV NC: empty vector negative control; com p21: the common p21cip1; var p21: variant p21cip1.
For the cells transfected with p21cip1: the light grey bars represent the non-transfected cells (cells negative for p21cip1, p21-) and the dark grey bars represent
the transfected cells (cells that were positive for p21cip1, p21+). The top of the bars represent the mean. The error bars represent the SEM. Panel B: p21
positive cells only. The fraction of cells in the G1 phase of the cell cycle normalised to control. EV NC: empty vector negative control. P21-: non-transfected
cell population within the same wells. White bars: p21 positive population as a percentage of the EV NC (100% represents G1 fraction identical to that seen in
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Since there are no adequate cellular models to study the effect of p21cip1 SNPs on AD-type
protein expression, we analysed these relationships in a series of post mortem brain samples
from AD patients and controls. In the post-mortem study, we found that p21cip1 levels were
raised in brain regions affected by AD. The expression of p21cip1 protein was most strongly de-
pendent on the accumulation of tangle pathology, and was independent of the p21cip1 genotype
or p21cip1 mRNA levels. The fact that p21cip1 protein expression was only related to tangles,
but not to the p21cip1 mRNA or to the amyloid component of the pathology, would suggest
that the p21cip1 protein may bind non-specifically to tangles as previously described [39,67,68].
Therefore, in post-mortem studies, the raised expression of p21cip1 protein in the AD brain
may be an artefact due to inappropriate accumulation, rather than a cause of AD-type protein
expression as suggested by in vitro studies [53]. On the other hand, the finding of p21cip1 over-
expression in peripheral lymphoblasts of AD patients does warrant further investigations into
the role of the protein in the disease process [69,70].
EV NC cultures). Black bars: p21 positive population as percentage of the p21- population (100% represents G1 fraction identical to that seen in p21- cells).
X-axis: com p21: the common p21cip1; var p21: variant p21cip1. The top of the bars represent the mean. The error bars represent the SEM. Panel C: The
fraction of cells in the G2 phase of the cell cycle (from the euploid population) in the different cell populations. EV NC: empty vector negative control; com p21:
the common p21cip1; var p21: variant p21cip1. For the cells transfected with p21cip1: the light grey bars represent the non-transfected cells (cells negative for
p21cip1, p21-) and the dark grey bars represent the transfected cells (cells that were positive for p21cip1, p21+). The top of the bars represent the mean. The
error bars represent the SEM. Panel D: p21 positive cells only. The fraction of cells in the G2 phase of the cell cycle normalised to control. EV NC: empty
vector negative control. P21-: non-transfected cell population within the same wells. White bars: p21 positive population as a percentage of the EV NC (100%
represents G2 fraction identical to that seen in EV NC cultures). Black bars: p21 positive population as percentage of the p21- population (100% represents
G2 fraction identical to that seen in p21- cells). X-axis: com p21: the common p21cip1; var p21: variant p21cip1. The top of the bars represent the mean. The
error bars represent the SEM. Panel E: The fraction of apoptotic cells (from single cell population) in the different cell populations. EV NC: empty vector
negative control; com p21: the common p21cip1; var p21: variant p21cip1. For the cells transfected with p21cip1: the light grey bars represent the non-
transfected cells (cells negative for p21cip1, p21-) and the dark grey bars represent the transfected cells (cells that were positive for p21cip1, p21+). The top of
the bars represent the mean. The error bars represent the SEM. Panel F: p21 positive cells only. The fraction of apoptotic cells normalised to control. EV NC:
empty vector negative control. P21-: non-transfected cell population within the same wells. White bars: p21 positive population as a percentage of the EV NC
(100% represents apoptotic fraction identical to that seen in EV NC cultures). Black bars: p21 positive population as percentage of the p21- population (100%
represents apoptotic fraction identical to that seen in p21- cells). X-axis: com p21: the common p21cip1; var p21: variant p21cip1. The top of the bars represent
the mean. The error bars represent the SEM. Analysis was carried out from 8 technical replicates of more than 5000 cells each.
doi:10.1371/journal.pone.0114050.g010
Figure 11. The effect of the p21cip1 genotype on beta-actin expression. The graph shows the amount of
beta-actin detected per cell expressed as a percentage change relative to the empty vector negative control.
Beta-actin expression was determined by Acumen Cytometry with beta-actin immunostaining: with the total
amount of beta-actin detected divided by the total number of cells in the sample. The cells were not double
stained for p21cip1 protein, so we were unable to differentiate the p21cip1 positive population (transfected
cells) from the p21cip1 negative population (non-transfected cells). X-axis: EV NC: Empty vector negative
control; com p21: cells transfected with common p21cip1; var p21: cells transfected with variant p21cip1. The y-
axis represents the percentage change in beta-actin expression per cell relative to the EV NC. The top of the
bars represent the mean. The error bars represent the SEM.
doi:10.1371/journal.pone.0114050.g011
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Confirming the result of a previous study [23], we found an association between the p21cip1
variant and AD. The variant was associated with a relatively small but significantly increased
risk of AD.
Although the variant was associated with an increased risk of PD with dementia relative to
age matched controls, it was not associated with dementia in PD relative to non-demented PD
patients. The latter could be the result of the relatively small patient numbers in the two groups.
Since dementia is mostly attributed to the appearance of AD-type pathology in PD patients
[71,72], it is not surprising that the relative frequency of the variant allele and the associated
odds ratios are very similar in the AD and PD with dementia groups. Prior to the age of 75, the
variant was associated with a reduction in the dementia free survival, in relation to both AD,
and PD with dementia. This effect disappeared above the age of 75. Age is the strongest risk
factor for both AD and dementia associated with PD. The data indicates that this risk is in-
creased by the relatively weak effect of the p21cip variant in younger people by bringing the age
of onset forward. However, in older patients (above the age of 75) the general effect of age pre-
dominates and the effect of the p21cip1 variant disappears.
Additionally, the SNPs were associated with an earlier age of onset of dementia in AD, and
a more severe AD phenotype, with a primary influence on the accumulation of tangle patholo-
gy in brain regions that are affected relatively late in the disease process. This, and the lack of a
similar relationship between the SNPs and temporal lobe pathology, may be a reflection of the
fact that the tau accumulation in the temporal lobe may have reached a ceiling in the patients,
whilst the formation of tau-related pathology in the frontal and occipital regions was still ongo-
ing. The genotype-phenotype correlation also suggests that the p21cip1 SNPs have a direct effect
on p-tau accumulation and NFT formation consistent with the involvement of cell cycle dereg-
ulation in the pathogenesis of AD. The finding is also consistent with recent findings of defi-
cient p53-dependent DNA damage repair, which requires a fully functional p21cip1 [59] in AD
[73]. However, we found no relationship between the p21cip1 SNPs and amyloid accumulation
in the same brain regions. This may be partly due to the fact that beta-amyloid accumulation
tends to reach a plateau early in the disease process. Alternatively, the complex relationship
between DNA-damage-repair signalling, apoptosis and beta amyloid [74] may be dependent
on other risk factors (genetic and environmental) that either have a stronger effect on beta-
amyloid accumulation than these SNPs or alter the effect of them.
Historically, the ApoE4 risk factor has been associated with a significantly more severe AD-
type pathology in post mortem series [75,76]. A relatively recent review found that several
other identified genetic risk factors for AD show no similar genotype-phenotype relationship
[77] suggesting that these SNPs, whilst affecting AD susceptibility, do not have a direct effect
on tau and amyloid accumulation. The relationship between an earlier age of onset and more
severe tangle pathology and the functionally defective p21cip1 variant supports the hypothesis
that the p21cip1 variant, by contributing to the loss of cell cycle control in neurons, is directly
involved in the pathogenesis of AD [38,39].
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S1 Table. Demographic data on the patient groups included in the genotyping study. CON-
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IV); Advanced AD: Neocortical stage Alzheimer’s disease (Braak V and VI).
(XLS)
S3 Table. Data in PM study. Pre-clinical: Entorhinal stage Alzheimer’s disease (Braak I and
II); Mild AD: Limbic stage Alzheimer’s disease (Braak III and IV); Advanced AD: Neocortical
stage Alzheimer’s disease (Braak V and VI). Protein measures (p-tau and p21) are arbitrary
units from ELISA assay. SEM: Standard Error of the Mean.
(XLS)
S4 Table. Different cell populations as measured by flow cytometry. EV NC: empty vector
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